Encephalitis Drugs Market Segmentation:
Disease Type Segment Analysis
The primary encephalitis is projected to hold 69.7% of the encephalitis drugs market share by 2037, owing to the rising prevalence of the infections. The surge in vector-borne diseases, due to the change in the climate, aggravates the cases. According to the World Health Organization in 2023, primary encephalitis accounts for 71% of the global cases, with 50,000 deaths per year. Other than this, primary encephalitis is considered to be 5 times more prevalent than other varieties. There is availability of targeted antiviral treatments, upgrading the management of the cases of primary encephalitis.
Treatment Type Segment Analysis
The antiviral agents’ segment is projected to garner 40.6% of the share by 2037 due to their efficiency in treating viral encephalitis diseases. Countries such as Japan and India include antivirals in national essential medicine lists for outbreaks of encephalitis. In India, the Indian Council of Medical Research (ICMR) tests remdesivir as a repurposed antiviral. The outbreaks in Japan for encephalitis cause 5000+ cases per year, fueling the demand for a wide range of anti-viral medicines such as favipiravir. Also, in the U.S., acyclovir antiviral, lowers the mortality for HSV encephalitis by 10-21%, fueling its adoption.
Our in-depth analysis of the global encephalitis drugs market includes the following segments:
|
Segment |
Subsegment |
|
Disease Type |
|
|
Treatment Type |
|
|
Administration |
|
|
End user |
|
|
Distribution Channel |
|
